Wegovy oral pill claims early US lead over Lilly's Foundayo as Novo Nordisk Q1 results approach

Key takeaways

• The FDA approved Novo Nordisk's Wegovy oral pill (semaglutide 25 mg) on 22 December 2025, the first oral GLP-1 approved for weight management. Eli Lilly's orforglipron (branded Foundayo) followed on 1 April 2026.
• Cross-trial average weight loss favours Wegovy oral (16.6%) over Foundayo (12.4%) at highest doses, but no head-to-head trial has been run.
• Foundayo's product profile differs in two important ways: it is a small-molecule (non-peptide) drug, and it can be taken at any time of day without food or water restrictions.
• The compounded-semaglutide grace period under FDA enforcement discretion is now closed; commercial pricing has dropped substantially with Wegovy oral starting at around $149/month in the US.
• In the UK, NICE has approved injectable Wegovy for over 1.2 million cardiovascular patients on the NHS. The oral pill remains under MHRA review.
• Novo Nordisk reports Q1 2026 results on 6 May. Analyst consensus expects approximately 8% revenue decline year-on-year.

The two products now in the US market

Wegovy oral is once-daily semaglutide 25 mg, the same active ingredient as the injectable Wegovy and Ozempic, reformulated for oral absorption. The FDA approved it on 22 December 2025 for weight management and reduction of major adverse cardiovascular events (Novo Nordisk press release, Applied Clinical Trials). It is now broadly available through more than 70,000 US pharmacies including CVS and Costco, plus telehealth providers and direct-to-consumer channels (Novo Nordisk availability release).

Foundayo (orforglipron) is a once-daily small-molecule oral GLP-1 receptor agonist — distinct from the peptide-based Wegovy oral — approved by the FDA on 1 April 2026 for adults with obesity or weight-related comorbidities. Lilly highlighted that Foundayo can be taken at any time of day without food or water restrictions, removing a usability constraint that the Wegovy pill carries (Lilly investor release, Pharmacy Times). Foundayo became the fifth approval under the FDA's Commissioner's National Priority Voucher pilot programme, issued 50 days after filing.

What the trial data says

Direct comparison must be hedged because there is no head-to-head trial. With that caveat:

• Wegovy oral: 16.6% average weight loss versus 2.7% placebo over 64 weeks in the OASIS-4 trial, in patients who remained on treatment (Endocrinology Advisor).
• Foundayo: 12.4% average weight loss versus 0.9% placebo at the highest dose in the ATTAIN-1 trial, on-treatment (AJMC on Foundayo approval).

On weight loss alone Wegovy oral has the edge. Foundayo's positioning is convenience plus small-molecule manufacturing economics — it does not require the more complex peptide synthesis pipeline, which Lilly believes will translate to scale and supply advantages.

The compounding picture

FDA enforcement discretion for compounded semaglutide ended on 22 May 2025; tirzepatide had ended in late 2024. The agency has since proposed excluding both, plus liraglutide, from the 503B Bulks List entirely, with the public comment window closing 29 June 2026 (Pharmacy Times on FDA action). Compounded shipments of these substances have fallen sharply.

For research suppliers in the UK, the GLP-1 compounding crackdown is relevant context rather than direct regulatory pressure. The MHRA framework for research-use peptides is unchanged. What the GLP-1 cycle does illustrate is the speed at which a compounded category can move from grey to enforced, and the scale of adverse-event reporting that follows when patients self-administer compounded preparations from inconsistent sources.

UK position

NICE issued draft guidance in March 2026 recommending injectable Wegovy (semaglutide 2.4 mg weekly) for over 1.2 million UK adults who have had a previous heart attack, stroke or peripheral arterial disease and a BMI of 27 or more. Final guidance is expected in May 2026, with NHS Integrated Care Boards required to make the drug available within 90 days (NHS England, NICE). This is independent of the existing NICE recommendation for weight management.

The oral Wegovy formulation has not yet been approved by the MHRA. UK timing depends on Novo Nordisk's filing strategy and is unconfirmed publicly.

Tomorrow's earnings

Novo Nordisk publishes Q1 2026 financial results on 6 May. Analyst consensus expects revenue to decline approximately 8% year-on-year, reflecting compounding-driven price pressure on the legacy injectable products and the cost of launching Wegovy oral. Markets will look for: oral pill prescription run-rate; gross margin impact of the new formulation; and any guidance update reflecting Foundayo's first-month uptake.

What to watch

Three market signals are worth tracking over the next month. First, weekly prescription data from US pharmacies — the early lead between the two oral products will likely calcify quickly given consumer preference for convenience. Second, NICE final guidance publication on injectable Wegovy in May, and any signal on oral pill review timing. Third, Lilly's manufacturing scale-up commentary on Foundayo, including the new $6.5 billion Houston facility supplying orforglipron API.

For research procurement, the GLP-1 wave continues to drive interest in adjacent peptide research and to set the public's reference frame for what "peptide therapy" means. That reference frame matters when buyers and end-users assess research-grade suppliers.